Tg(APOB*Q2153L)#Boren

The transgene contains the full-length human apolipoprotein B gene with a CAA to CTA point mutation in codon 2153, which results in the replacement of glutamine by leucine (Q2153L). Loss of the CAA prevents its conversion to the stop codon UAA by a liver mRNA editing mechanism, abrogating production of apo-B48 and increasing the yield of the full-length translation product, apo-B100. This mutation is called "apo-B100 Leu-Leu" in the literature because conversion by mRNA editing of the C in the mutant leucine-encoding CTA codon to U would yield UUA, which also encodes leucine. (J:262089)